Sentences with phrase «of big pharma companies»

Not exact matches

Big biotech and pharma companies are absolutely dependent on being able to successfully innovate by partnering with and acquiring disruptive startups because of the nature of the patent cliff in pharmaceuticals.

In periods of rising volatility, pharma companies are often especially vulnerable because of investors are paying big prices today for therapies expected to pay off over a long horizon.

The «microbiome,» or the collection of organisms that reside within the human body (especially the gut), has become a big new interest area for a number of major pharma companies like Merck and smaller biotechs alike.

The report points to a number of factors driving big pharma companies» struggles with netting strong returns, including a dearth of late - stage pipeline candidates and diversified product portfolios that aren't necessarily spreading risk.

Many of the recent Big Pharma deals and acquisition proposals have been motivated by the companies» desire to lower their tax rate by acquiring a foreign rival and moving their headquarters overseas in a process known as an inversion.

Giddying merry - go - round of pharma deals continues as Israeli company creates the world's biggest maker of generics.

Add one more name to the new slew of pharma companies trying to counteract the public backlash to big drug price increases: France's Sanofi, a $ 126 billion firm known for its flagship diabetes and vaccines units.

The intense, full - day strategy sessions invariably ended with Cornelius getting a headache, he says — particularly when he sparred with executives in the company who clung to vestiges of big, fat pharma.

One day I came home from working at a big pharma company that had the same type of elevator as my condo building in Toronto.

At a moment when the world's fourth - largest pharmaceutical company by sales (Pfizer) is eagerly courting the world's ninth - largest (the very same AstraZeneca from which Bristol decoupled)-- offering, in late May, a monumental dowry of around $ 120 billion — one can be forgiven for not noticing the more substantive change that's sweeping the pharmaceutical industry: Big Pharma is getting smaller.

Immuno - oncolocy has been the focus of Big Pharma and biotechs alike, with companies such as Merck (mrk), Bristol - Myers Squibb (bmy), Pfizer (pfe), Roche / Genentech, Juno (juno), Kite Pharma (kite), Novartis (nvs), and countless others pouring massive investments into the space (the Loncar ETF contains almost all of these companies).

We cover biopharma companies end - to - end — whether they're small, specialty drugmakers, generics companies or the biggest of Big Pharma — highlighting the accomplishments and acknowledging the defeats that all of them experience in the complicated, competitive pharmaceuticals industry.

US: Heather Bresch, the CEO of Mylan, an American pharmaceuticals company, finds herself at the center of one of the biggest pharma controversies in recent years: price - gouging.

And big players like J&J have been successful in stalling the competition through a framework of deals with the companies managing pharma benefits in the US.

The technology is allowing basic scientists and small companies to generate impressive libraries of molecules, on a scale once reserved for big pharma, and select from them the most useful compounds.

I know probably 20 + recent grads from these types of programs — only two of them have a CV that is likely to even make them a viable candidate for a position to get them in the door at a big pharma company.

«In terms of learning potential, I thought that there would be more to learn in a small biotech company than in big pharma,» he explains.

But in the world of big pharma, Gervais warns, not all other companies encourage publishing and may take a more defensive position regarding the release of information.

Big pharma and companies that produce everything from tinned beans to toothpaste are major employers of chemists, but it can pay to look beyond these giants.

The immediate payoff was a commercialization deal in age - related macular degeneration in which Pfizer became the first big pharma company to make a move into the use of embryonic stem cells as the basis for a tissue regeneration therapy.

For example, if you and your fellow postdocs would like to learn about career opportunities in industry and biotech, you'll need to invite a variety of companies focusing on areas ranging from clinical trials to biotech start - ups to big pharma.

Creating new opportunities for «all of these very talented, experienced, displaced workers» requires «getting them thinking creatively about maybe making the move from big pharma, where they've spent their careers,» to other opportunities, such as smaller, newer companies created by themselves, perhaps, or other displaced scientists.

Some of the diagnostics companies, for instance, are expanding, and there's been an influx of big pharma into the area recently.»

«Smaller companies, I think, are in a position to provide some of the early - stage work that big pharma used to do in - house.»

Like other big pharma companies, Pfizer is partnering with academic institutions to share the risk of drug development and take advantage of academic scientists» broad base of knowledge, says Boston - based Anthony Coyle, vice president of the Centers for Therapeutic Innovation (CTI) at Pfizer.

In the race to develop an Ebola vaccine, a small cancer therapy company, NewLink Genetics, has been in the shadows of GlaxoSmithKline (GSK), a big pharma company with lots of experience and far deeper resources.

With more than 1,200 international actors from 35 + countries, such as big pharma, emerging and small biotech, diagnostics companies, pre-seed / seed / Series A investors, as well as professionals from tech transfer, academia and research institutions, BioFIT is the leading partnering event in Europe for technology transfer, academia - industry collaborations and early - stage innovations in the field of Life Sciences.

I have cursed the Big Pharma Companies for their failure to take risks and their fierce guarding / not sharing of proprietary discovery — their parochial - ness.

Unbound The Strange and Very American Liberation of Big Pharma THE MAN IN THE ARENA: WHY PHARMACEUTICAL COMPANIES BECAME SO AGGRESSIVE

This Shanghai - based R&D company is winning a lot of outsourcing business from big pharma: 66 % comes from China, and 34 % is in the U.S..

That is certainly been shown by the performance of «Big Pharma» companies such as Eli Lilly (NYSE: LLY), Merck (NYSE: MK), and Pfizer (NYSE: PFE) in recent market action.

That is certainly been shown by the performance of «Big Pharma» companies such as Eli Lilly (NYSE: LLY), Merck (NYSE: MK), and Pfizer (NYSE: PFE) in recent -LSB-...]

It certainly bears noticing that these disease «alerts» are coming fast and furious — but only for diseases that have a vaccine ready to go, and ready to make some Big Pharma company boatloads of money.

Long - term studies of animal immunity would require a substantial outlay of money — the kind of money that only the drug companies have, and Big Pharma is much more interested in selling more vaccines than challenging the need for them.

Similarly, biomedical and pharmaceutical research is bedazzled by molecular genetics, has sequenced the genome of one or two humans and a handful of other species and invested trillions on very rigidly reductionistic bottom - up research into medicines and diseases — with the result of empty drug pipelines for the big pharma companies in spite of all this investment.

Oncology drug development continues to see a high level of activity and funding across the US, despite an uncertain regulatory environment that has left many Big Pharma companies carefully considering their R&D investments and strategies.

A number of big pharma will continue to drive M&A activity through 2015 & 2016 where larger companies such as Pfizer and Teva have both the appetite and the cashflow to look at investments that support existing divisions.

We work hard to help employers find the best available applicant for both mid and upper level positions across a wide range of organisations, from CROs and big pharma, though to smaller companies.

Outside of Immunotherapy there has been a steady rise in companies pushing generic and biosimilar drugs over the last 12 months, something of which the Big Pharma organisations are attempting to resist.

Big pharma companies have merged, they're having pipeline issues, and TONS of pharma reps have been laid off.

But I saw it recently, and it's a little like watching a train wreck: this woman wrote a book called Big Pharma's Sexy Little Secret about how (and it's possible I've missed everything there is to see here...) pharmaceutical companies purposely hire «cheerleader» types so that they can use sex — or the idea of it, anyway — to manipulate doctors into buying more of their product.

I think you'll see a continuation of big pharma merging with bio-tech to get the technology and talent that resides in those companies.